Acute & maintenance treatment of schizophrenia in adults stabilized w/ oral aripiprazole. Maintenance monotherapy treatment of bipolar I disorder in adults.
Initially 1 IM inj, continue treatment w/ oral aripiprazole 10-20 mg daily for 14 days or 2 separate IM inj w/ oral aripiprazole 20 mg. Maintenance dose: 400 mg once mthly as single IM inj, no sooner than 26 days after previous inj. May reduce dose to 300 mg once mthly if AR occur.
Hypersensitivity reactions. Not to be inj IV or SC. Not indicated for dementia-related psychosis. Avoid inadvertent inj into blood vessel. Suicidal behaviour; known CV & cerebrovascular disease or other conditions predisposing to hypotension or HTN; VTE; history of QT prolongation & seizures. Tardive dyskinesia; NMS; hyperglycemia & DM; wt gain; pathological gambling & impulse-control disorders; somnolence, postural hypotension, motor & sensory instability leading to falls, fractures & other injuries; orthostatic hypotension. Patients at risk for aspiration pneumonia. Avoid concomitant use w/ CYP3A4 inducers. Concomitant use w/ strong CYP2D6 &/or CYP3A4 inhibitors. May affect ability to drive & use machines. Severe hepatic impairment. Not to be used during pregnancy. Lactation. Childn & adolescents ≤17 yr. Elderly ≥65 yr.
Sign Out
 400 mg8ac4bc07-0f11-4149-8cb9-a9d200980e10.GIF)
